| Literature DB >> 32190664 |
Liling Deng1,2, Tao Chen1, Huan Xu3, Yuanmei Li1, Mingyan Deng1, Dan Mo1, Haoming Tian1, Yan Ren1.
Abstract
OBJECTIVE: The aim of this study was to investigate the expression of Snail, galectin-3, and IGF1R in benign and malignant pheochromocytoma and paraganglioma (PPGL) and explore their role in the diagnosis of malignant PPGL.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32190664 PMCID: PMC7066411 DOI: 10.1155/2020/4150735
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Clinical characteristics of the study patients.
| Benign PHEO ( | Benign PGL ( | Potentially malignant PPGL ( | Malignant PPGL ( |
| |
|---|---|---|---|---|---|
| Gender (male/female) | 50/46 | 18/20 | 28/50 | 6/8 | 0.269 |
| Age | 49.63 ± 14.83 | 53.11 ± 13.69 | 45.43 ± 14.68 | 39.35 ± 15.34 | 0.008 |
| Tumor size (cm) | 5.0 (3.5-7.0) | 5.0 (4.0-6.0) | 5.0 (4.0-8.0) | 6.5 (3.25-10.5) | 0.158 |
| Blood NE (ng/L) | 1198.0 (543.5-3948.0) | 1343.5 (662.5-2815.5) | 2603 (1000-6004) | 1129.5 (646.3-378) | 0.081 |
| Blood E (ng/L) | 69.5 (41.6-226.3) | 74 (48-200) | 103.5 (50-376.3) | 61 (50-94) | 0.228 |
Figure 1Cumulative Kaplan-Meier survival curves.
Figure 2Snail immunostaining in PHEO and PGL. (a) Intense staining of Snail in positive control tissue (breast carcinoma) (Zeiss imager ×400). (b) Intense nuclear staining of Snail in PPGL tumor tissue (Zeiss imager ×400). (c) Weak nuclear staining of Snail in PPGL tumor tissue (Zeiss imager ×400). (d) Intermediate nuclear staining of Snail in PPGL tumor tissue (Zeiss imager ×400). (e) Negative nuclear staining of Snail in PPGL tumor tissue (Zeiss imager ×400). (f) Negative nuclear staining of Snail in normal adrenal glands (Zeiss imager ×100).
Snail IHC expression in PPGLs.
| Negative ( | Weakly positive ( | Intermediately positive ( | Strongly positive ( |
|
| |
|---|---|---|---|---|---|---|
| Benign PHEO ( | 60 (62.5) | 30 (31.3) | 5 (5.2) | 1 (1.0) | ||
| Benign PGL ( | 13 (34.2) | 11 (28.9) | 8 (21.1) | 6 (15.8) | 37.121 | <0.001 |
| Potentially malignant PPGL ( | 15 (19.2) | 32 (41.0) | 18 (23.1) | 13 (16.7) | ||
| Malignant PPGL ( | 3 (21.4) | 0 (0) | 2 (14.3) | 9 (64.3) |
Figure 3Cumulative Kaplan-Meier survival curves—Snail immunostaining intensity.
Figure 4Galectin-3 immunostaining in PHEO and PGL. (a) Intense staining of galectin-3 in positive control tissue (lung carcinoma) (Zeiss imager ×200). (b) Intense cytoplasm staining of galectin-3 in PPGL tumor tissue (Zeiss imager ×400). (c) Intermediate cytoplasm staining of galectin-3 in PPGL tumor tissue (Zeiss imager ×400). (d) Weak cytoplasm staining of galectin-3 in PPGL tumor tissue (Zeiss imager ×200). (e) Negative cytoplasm staining of galectin-3 in PPGL tumor tissue (Zeiss imager ×100). (f) Negative cytoplasm staining of galectin-3 in normal adrenal glands.
Galectin-3 IHC expression in PPGLs.
| Negative ( | Weakly positive ( | Intermediately positive ( | Strongly positive ( |
|
| |
|---|---|---|---|---|---|---|
| Benign PHEO ( | 72 (75.0) | 22 (22.9) | 2 (2.1) | 0 (0) | ||
| Benign PGL ( | 10 (26.3) | 14 (36.8) | 12 (31.6) | 2 (5.3) | 76.741 | <0.001 |
| Potentially malignant PPGL ( | 13 (16.7) | 34 (43.6) | 17 (21.8) | 14 (17.9) | ||
| Malignant PPGL ( | 1 (7.1) | 0 (0) | 6 (42.9) | 7 (50) |
Figure 5Cumulative Kaplan-Meier survival curves—galectin-3 immunostaining intensity.
Figure 6IGF1R immunostaining in PHEO and PGL. (a) Intense cell membrane and cytoplasm staining of IGF1R in positive control tissue (breast carcinoma) (Zeiss imager ×200). (b) Intense cytoplasm staining of IGF1R in PPGL tumor tissue (Zeiss imager ×400). (c) Intermediate cytoplasm staining of IGF1R in PPGL tumor tissue (Zeiss imager ×400). (d) Negative cytoplasm staining of IGF1R in PPGL (Zeiss imager ×400).
IGFR1 IHC expression in PPGLs.
| Negative ( | Weakly positive ( | Intermediately positive ( | Strongly positive ( |
|
| |
|---|---|---|---|---|---|---|
| Benign PHEO ( | 73 (76.0) | 22 (22.9) | 1 (1.1) | 0 (0) | ||
| Benign PGL ( | 13 (34.2) | 8 (21.1) | 6 (15.8) | 11 (28.9) | 75.693 | <0.001 |
| Potentially malignant PPGL ( | 12 (15.4) | 24 (30.8) | 14 (17.9) | 28 (35.9) | ||
| Malignant PPGL ( | 2 (14.3) | 0 (0) | 3 (21.4) | 9 (64.3) |
Figure 7Cumulative Kaplan-Meier survival curves—IGF1R immunostaining intensity.